{
    "clinical_study": {
        "@rank": "136137", 
        "arm_group": [
            {
                "arm_group_label": "Sarilumab (SAR153191, REGN88) Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy"
            }, 
            {
                "arm_group_label": "Sarilumab (SAR153191, REGN88)  Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy"
            }, 
            {
                "arm_group_label": "Sarilumab (SAR153191, REGN88) Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy"
            }, 
            {
                "arm_group_label": "Sarilumab (SAR153191, REGN88) Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy"
            }, 
            {
                "arm_group_label": "Placebo Dose 5", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the safety and tolerability of a single dose of subcutaneously administered\n      sarilumab in Japanese patients with rheumatoid arthritis (RA) who are receiving concomitant\n      treatment with methotrexate.\n\n      Secondary Objective:\n\n      To assess the pharmacokinetic profile of a single subcutaneous (SC) dose of sarilumab in\n      Japanese RA patients."
        }, 
        "brief_title": "Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total study duration per patient is up to 88 days\n\n        1. Screening: 3 to 28 days\n\n        2. Treatment: 1 day\n\n        3. Follow-up: 57\u00b1 3 days after dosing"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Male or female Japanese who are 20 to 65 years of age\n\n          2. Diagnosis of rheumatoid arthritis (RA) \u2265 3 months duration\n\n          3. Treated for a minimum of 8 weeks with Methotrexate (MTX) and with a stable dose of\n             MTX (6-16 mg/week) for a minimum of 4 weeks prior to the screening visit\n\n        Exclusion criteria:\n\n          1. Autoimmune or inflammatory systemic or localized joint disease other than RA\n\n          2. Women of  a positive pregnancy test\n\n          3. Latent or active tuberculosis\n\n          4. Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor\n             (IL-6R) antagonist\n\n          5. Treatment with anti-TNF agents, as follows:\n\n               1. Etanercept: within 28 days prior to randomization\n\n               2. Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to\n                  randomization\n\n          6. Received any live, attenuated vaccine within 3 months prior to the randomization\n             visit (eg, varicella-zoster, oral polio, rubella vaccines)\n\n          7. Significant concomitant illness such as, but not limited to, cardiovascular, renal,\n             neurological, endocrinological, gastrointestinal, hepato-biliary, metabolic,\n             pulmonary or lymphatic disease that would adversely affect the patient's\n             participation in the study.\n\n          8. Received surgery within 4 weeks prior to the screening visit or planned surgery\n             during the study\n\n          9. History of a systemic hypersensitivity reaction\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850680", 
            "org_study_id": "TDU13402", 
            "secondary_id": "U1111-1134-0048"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191, REGN88)  Dose 2", 
                    "Sarilumab (SAR153191, REGN88) Dose 3", 
                    "Sarilumab (SAR153191, REGN88) Dose 4", 
                    "Sarilumab (SAR153191, REGN88) Dose 1"
                ], 
                "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
                "intervention_name": "sarilumab SAR153191 (REGN88)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Dose 5", 
                "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191, REGN88)  Dose 2", 
                    "Sarilumab (SAR153191, REGN88) Dose 4", 
                    "Sarilumab (SAR153191, REGN88) Dose 3", 
                    "Sarilumab (SAR153191, REGN88) Dose 1", 
                    "Placebo Dose 5"
                ], 
                "description": "Pharmaceutical form:capsule Route of administration: oral", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sarilumab (SAR153191, REGN88)  Dose 2", 
                    "Placebo Dose 5", 
                    "Sarilumab (SAR153191, REGN88) Dose 1", 
                    "Sarilumab (SAR153191, REGN88) Dose 3", 
                    "Sarilumab (SAR153191, REGN88) Dose 4"
                ], 
                "description": "Pharmaceutical form:tablet Route of administration: oral", 
                "intervention_name": "folic acid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sendai-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Investigational Site Number 392002"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Assessment of safety parameters (adverse events, laboratory data, vital signs, and ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 88 days or end-of-study (EoS)"
            }, 
            {
                "measure": "Assessment of the occurrence of anti-sarilumab antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 15, Day 29, Day 57"
            }, 
            {
                "measure": "Assessment of the titer of anti-sarilumab antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 15, Day 29, Day 57"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850680"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of PK parameter - maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "At each visit, up to 88 days"
            }, 
            {
                "measure": "Assessment of PK parameter - area under curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "At each visit, up to 88 days"
            }, 
            {
                "measure": "Assessment of PK parameter - time to maximum concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "At each visit, up to 88 days"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}